[ Inside the business ]

BDX stock analysis

BDX · Becton Dickinson & Co

Surgical and medical instruments and apparatus. Growing 5%. Keeps 11¢ of every dollar.

Nothing unusual in its latest filings.

The future, in 7 questions

Priced in: 1.0× sales in 5 yrs. Evidence: sales +5% · 11¢ profit/$1.

01 What's priced in?1.0× sales in 5 yrs
Sales now$22.5B
Needed in 5 yrs$23.4B
02 Is the wave rising?No Radar technology matched

Not among the companies mentioning Radar's technologies most.

03 Will customers keep buying?Sales +5%, steady
No customer over 10%
Prepaid $334MSales +5%, steady
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Keeps 11¢ per $1
'21'22'23'24'2511¢
Before running costs: 45% → 45%
06 Can it fund itself?Pays its own way
05 yrsself-funded
Shares +0.0%/yrDebt $16.8B
07 What could break it?1 to watch
  • Moves strongly with the Dollar

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth speeding up.

Sales growth +2%, +5%, then +5% vs. a year ago.

What could go wrong

Steadier than most.

It has moved 0.5× the market. In the 2008 crisis it fell 24% while the market fell 51%. Debt is heavy.

Speculative check

Self-funding.

Passes every condition: profitable, cash-generating and financially sound.

What they sell

Not broken out.

The filings don't split revenue by product in structured data.

Where each dollar goes

11¢ profit.

53¢ to make what it sells, 36¢ on research and overhead, 11¢ left over. Revenue $22.5B in the last 12 months.

Its market

0.3× the economy.

The government expects its industry, fabricated metal product manufacturing, to grow 0.7% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Maturity.

It earns cash, still invests, and pays back more than it borrows.

Earnings quality

Clean.

Its numbers don't resemble those of past manipulators.

Competitive advantage

1 of 10 years.

Returns beat its 6.2% cost of capital in 1 of the last 10 years. Gross margin went from 48% to 45%.

Future bets

6% on research.

$1.3B a year on R&D. $753M on equipment and buildings.

All figures from Becton Dickinson & Co's SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.